Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Biochemistry and Molecular Medicine Faculty
Publications

Biochemistry and Molecular Medicine

2013

Extraction of molecular features through exome to
transcriptome alignment
Prakriti Mudvari
George Washington University

Kamran Kowsari
George Washington University

Charles Cole
George Washington University

Raja Mazumder
George Washington University

Anelia Horvath
George Washington University

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs
Part of the Biochemistry, Biophysics, and Structural Biology Commons
Recommended Citation
Mudvari, P., Kowsari, K., Cole, C., Mazumder, R., Horvath, A. (2013). Extraction of molecular features through exome to
transcriptome alignment. Journal of Metabolomics and Systems Biology, 1(1):7.

This Journal Article is brought to you for free and open access by the Biochemistry and Molecular Medicine at Health Sciences Research Commons. It
has been accepted for inclusion in Biochemistry and Molecular Medicine Faculty Publications by an authorized administrator of Health Sciences
Research Commons. For more information, please contact hsrc@gwu.edu.

J Metabol Sys Biol
August 2013 Issue:1, Vol.:1
© All rights are reserved by Anelia Horvath et al.

Extraction of Molecular Features
through Exome to Transcriptome
Alignment
Keywords: Exome; Transcriptome; Breast Tumor; Breast Cancer; SNP;
Allelic Imbalance; Allele Preferential Expression; RNA Editing; Somatic
Mutations; Imprinting; LOH

Introduction
With the evolution of next-generation sequencing (NGS)
technologies, the time, cost and amount of the material needed are
constantly declining, thus making applications such as genome/
exome and transcriptome sequencing increasingly feasible. As a result,
a rapidly growing number of exomes, genomes and transcriptomes
from the same individual are accumulating, providing unique venues
for mechanistic and regulatory feature analysis, and, at the same
time, requiring new exploration strategies. To date, only a handful
of studies have integrated NGS genome scale datasets. Nevertheless,
these studies have provided essential functional and regulatory
insights, reaching far beyond linear addition of individual NGS
dataset information layers, and often unraveling novel diagnostic and
therapeutic targets [1-6].
Commonly explored algorithms for genomic data integration
include alignment of germ line and somatic DNA in search for tissueand tumor-specific changes [6], exome/genome-to-transcriptome
comparison for pre- and post-transcriptional regulatory elements
[7], and non-coding transcriptome-epigenome-genome overlay for
assessment of encoded and acquired expression control [8-11]. In
our study, we focus on one relatively unexplored aspect of integrative
genomic analysis: SNP-centered allelic preferential expression at
nucleotide resolution using exome and transcriptome data from the
same individual.
We have integrated the variation and expression information
of four NGS datasets from the same individual: germ-line exome,
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Abstract
Integrative Next Generation Sequencing (NGS) DNA and RNA
analyses have very recently become feasible, and the published to
date studies have discovered critical disease implicated pathways,
and diagnostic and therapeutic targets. A growing number of
exomes, genomes and transcriptomes from the same individual are
quickly accumulating, providing unique venues for mechanistic and
regulatory features analysis, and, at the same time, requiring new
exploration strategies. In this study, we have integrated variation and
expression information of four NGS datasets from the same individual:
normal and tumor breast exomes and transcriptomes. Focusing on SNPcentered variant allelic prevalence, we illustrate analytical algorithms
that can be applied to extract or validate potential regulatory
elements, such as expression or growth advantage, imprinting, loss of
heterozygosity (LOH), somatic changes, and RNA editing. In addition,
we point to some critical elements that might bias the output and
recommend alternative measures to maximize the confidence of
findings. The need for such strategies is especially recognized within the
growing appreciation of the concept of systems biology: integrative
exploration of genome and transcriptome features reveal mechanistic
and regulatory insights that reach far beyond linear addition of the
individual datasets.
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normal breast tissue transcriptome, and breast tumor exome and
transcriptome (Table 1). Focusing on nucleotide resolution allelic
imbalance, we explore different analytical algorithms to retrieve
potential encoded-to-regulatory links: expression/growth advantage
driving variations, tumor-related gross genomic alterations, somatic
changes, imprinting, and, RNA editing. We further discuss our
observations in the light of existing knowledge, and highlight
opportunities to integrate expression data through variation-toabundance analytical algorithms. Finally, we point to some critical
elements that might bias the output and recommend alternative
measures to maximize the confidence of the findings.

Materials and Methods
Short read data was obtained from The Cancer Genome Atlas
(http://cancergenome.nih.gov/) via the CGHub data portal (https://
cghub.ucsc.edu/). Short read datasets from a single patient with
exome and RNA-seq breast cancer tumor and normal tissue (TCGABH-A0B3) was selected for analysis. Additional information about
the patient and sample was retrieved from data matrix available at
https://tcgadata.nci.nih.gov/tcga/dataAccessMatrix.htm. The sample
details are as follows: Disease type - BRCA-Breast invasive carcinoma;
Data Type – Clinical; Race – White; History – no previous history of
malignancy; Platform – illumina. The tumor and the matched control
samples were identified by the TCGA bar code associated with the
sample. The sample type of RNA-seq case dataset (TCGA-BH-A0B301A-11R-A056-07) is Primary Tumor. The sample type of RNA-seq
control datasets (TCGA-BH-A0B3-11B-21R-A089-07) is Normal
Table 1: Sample attributes of data included in our study.
Sample ID

Sample
Type

Site

Sequencing
Technique

TCGA-BH-A0B3-01A11R-A056-07

Primary
Tumor

Breast Tissue RNA-seq

TCGA-BH-A0B3-11B21R-A089-07

Normal

Breast Tissue RNA-seq

TCGA-BH-A0B3-01A11W-A071-09

Primary
Tumor

Breast Tissue

Whole Exome
Sequencing

TCGA-BH-A0B3-10A01W-A071-09

Normal

Blood

Whole Exome
Sequencing
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Solid Tissue. The sample type of exome case datasets (TCGA-BHA0B3-01A-11W-A071-09) is Primary Tumor. The sample type of
exome control datasets (TCGA-BH-A0B3-10A-01W-A071-09) is
Blood Derived Normal. The data manifest was downloaded using the
‘cgquery’ script, which is available on the CGHub website (https://
cghub.ucsc.edu/). A manifest file was generated by specifying the
required characteristics, such as disease type, platform, tissue site,
etc. Once the manifest was generated, data was downloaded through
the ‘GeneTorrent’ software (also available on CGHub) in BAM
format. The BAM file is converted into the FASTQ format using the
‘bam2fastq’ program available through http://www.hudsonalpha.
org/-gsl/information/software/bam2fastq.
The raw reads were then aligned against Ensembl GRCh37 (hg19)
using Bowtie2 [12] for exome data and TopHat2 [13] for transcriptome
data. For transcript assembly, we utilized the Cufflinks from the
Tuxedo suite of programs [14]. We used the default parameters
during the analysis, which filters low abundance transcripts that
comprise 10% of the most abundant isoform. The variants were called
using mpileup utility of Samtools [15] with default settings except for
the maximum read depth, which was set to 8,000. The variation calls
were annotated through SeattleSeq v.137 (http://snp.gs.washington.
edu/SeattleSeqAnnotation137/). To minimize false negative and false
positive calls, we applied filtering as previously described [16]. Briefly,

previously reported SNPs, due to independent validation by other
group(s), were analyzed further without filtering. The novel variants
were required to satisfy the following criteria optimized by our group:
supported by a minimum of four bidirectional reads with unique start
position, phred quality value (QUAL) > 20, and mapping quality value
(MQV)>20. For visual evaluation of positions of interest, we utilized
Integrative Genomic Viewer (IGV, http://www.broadinstitute.org/
software-/igv/home [16,17].

Results
Prior to integration of the datasets, all variants were called and
annotated individually in the four datasets, and abundance was
estimated for the transcriptomes. To extract observations with high
confidence, we analyzed the above features only in regions well
covered in all four datasets. To maximize the informative overlap
between the exome and transcriptome, we filtered out data from
intergenic and intronic regions. As an initial step for the integrative
analysis, we mapped all the SNPs called in at least one dataset, and
displayed the wild type (wt) and variant (var) calls in absolute and
relative (var/wt) numbers for all four datasets. The major steps of our
analytical algorithm are presented in (Figure 1).
Overlay of the four datasets revealed several intriguing
observations (Figure 1A). First, both normal and tumor transcriptome

Figure 1: Schematic representation of the overlay between four different NGS SNP datasets from the same individual: Normal Exome derived (NE), Normal
Transcriptome (NT), Tumor Exome (TE) and Tumor Transcriptome (TT). (A) Number of SNPs exclusive and shared between the different datasets. (B) Analytical
algorithms to extract regulatory features through comparison of the allelic representation of the variant and wild type read representation at the nucleotide position
of the SNP.
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displayed more SNPs as compared to the corresponding exomes
(Table 2). More than 70% of the variants seen in the transcriptome
and not in the exome overlapped between the normal and the
tumor datasets. When we analyzed the variants by annotation type,
we found that the major proportion of the transcriptome exclusive
variants (78% and 67%, for the normal and the tumor, respectively)
belong to 3’ and 5’UTRs. Such a result is logical due to the widely used
exome capture design that includes only the UTR regions immediate
to the coding sequences. Therefore, most of the UTR variants called
are outside the exome capture target. In contrast, since these regions
are transcribed, they are readily included in the transcriptome and
thus comprise the major variant-based difference between the
exome and the transcriptome.
From the remaining, at least half are called with 5 or less reads, with
some proportion of those likely to represent false positives, especially
the ones not listed in the human variation databases (referred
hereafter as “novel”). A portion of the non-UTR transcriptomeexclusive variants likely reside outside of the exome capture capacity
and, finally, a small percentage may represent post-transcriptional
modifications, including RNA editing events.
To outline preferentially expressed SNP bearing alleles, we
extracted all transcriptome SNPs called with var/wt ratio higher than
2 (var/wt > 2), and, called heterozygote in the respective exomes
(Figure 1A). Overlap of thus selected normal and tumor datasets
revealed higher-confidence preferentially expressed SNPs, and the
ones exclusive for the tumor set defined a subset of potential tumorspecific changes. From the preferentially expressed alleles, a particular
over-selected subset consists of the novel SNPs, due to the minimal
possibility to be present in homozygote state on genomic level. For
high confidence findings on this dataset, we further tightened the
criteria for strong allele preferential expression to var/wt > 5. This
revealed thirty-one SNPs, all present in the population databases,
shared between the normal and the tumor datasets; seven of them were

homozygous in both transcriptomes. When we looked in the tumorspecific allele-preferential expression, we found 683 SNPs with strong
allele-preferential expression exclusive for the tumor transcriptome;
from them, 11 were novel (not present in the databases) and 343 were
in homozygous state.
Several molecular mechanisms may account for preferential
expression of genomically heterozygous SNPs in the normal
transcriptome. Among the common causes are imprinting, caused
by the exclusive expression from only one of the parental alleles, and,
cis-acting expression advantage provided by the allele harboring
the SNP. In some cases this might be caused by the nucleotide
change contained in the SNP of interest, through either creation
or disruption of regulatory molecule(s) binding element. In our
dataset, an example of imprinting is illustrated by the known SNP
(rs2192206) in the gene encoding the growth suppressor necdin
NDN (Table 3). NDN is known for its exclusively paternal expression
[19]; rs2192206 presented with well-balanced heterozygous signal
in both exomes and monozygotic expression of the variant allele in
both transcriptomes (Figure 2A). In contrast, rs73231013 in the gene
encoding the nucleosome binding protein HMGN5 shows similar
expression pattern (Figure 2B) without acknowledged involvement
of imprinting processes. Whether the SNP rs73231013 in HMGN5 is
molecularly implicated in the increased allelic expression is a subject
of future large-scale validation and focused wet-lab studies.
In the tumor setting, a common cause for allelic expression is the
elimination of one of the alleles, in many cases the wild type, through
the mechanism of LOH. Because LOH occurs at DNA level, such
SNPs can be identified by their homozygote vs heterozygote state in
the tumor and the normal exomes, respectively. In our dataset, 214
SNPs, five of which are novel, matched these conditions. Since LOH
usually affects large genomic regions, one additional distinguishing
feature would be the coexistence, in an uninterrupted fashion, of
similarly transitioned hetero-to-homozygote SNPs (from normal

Table 2: Number of SNPs exclusive and shared between the four analyzed datasets.
Individual SNP
Tumor and
count
normal
(known/
overlap
novel)

Exclusive for
Exclusive for
transcript-tome exome

Transcriptomes Overlap

TT

29013 / 6075

19187 / 4097

20070 / 897

TE

20978 / 310

NT

32403 / 4229

NE

23149 / 402

SNPs
Sample

10163 / 108
13216 / 130

9803 / 270

Exomes
Overlap

Exclusive for
Normal

Exclusive for
tumor

Total
overlap

8878 / 5156
18405 / 156

18781 / 5945

2539 / 152
12339 / 3322

10776 / 200

8074 / 83

4617 / 244

Table 3: Illustrative examples of SNPs representing different regulatory features. The chromosomal coordinates of the change, the harboring gene, the functional
annotation, and the respective number of variation and wild type calls are presented for each SNP.
Number of reads (var/wt)*

Feature (putative)

Position and Change

Gene

SNP ID

Annotation

NE

NT

TE

TT

Imprinting

chr15:23931507 G>A

NDN

rs2192206

Coding-synonymous

26 / 18

40 / 0

11 / 5

15 / 1

Expression Advantage

chrX:80373961 C>T

HMGN5

rs73231013

Coding-synonymous

37 / 38

37 / 2

21 / 18

4/0

chr2:218682771 A>G

TNS1

rs3796026

Coding-synonymous

9 / 12

27 /49

2/1

12 / 2

Loss of Heterozygosity
(LOH)

chr2:219209796 C>A

PNKD

rs921970

3’ UTR

4/3

7/1

5/0

6/1

chr2:219503113 C>T

ZNF142

rs1803383

Coding-synonymous

5/6

9/6

7/0

37 / 4

chr2:220431631 G>T

OBSL1

rs1043537

Coding-synonymous

9/9

41 / 42

8/1

82 / 4

Growth Advantage

chr1:9305335 C>T

H6PD

rs138024142

Coding-synonymous

32 / 35

34 / 29

34 / 20

22 / 2

Somatic Mutation

chr17:7578203 C>T

TP53

COSM10667

Missense; V216M

0/0

0/0

19 / 34

93 / 9

RNA Editing

chr1:160319987 A>G

NCSTN

NA

Missense;S177G

0/0

0/0

0/0

42 / 89

* Total number of reads, before filtering for MQV; reads will MQV< 20 were removed from further analysis
J Metabol Sys Biol 1(1): 7 (2013)
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Figure 2: Integrative Genomics Viewer (IGV) representation of examples of SNP calls aligned between the four analyzed datasets: Normal Exome, Tumor
Exome, Normal Transcriptome, and Tumor Transcriptome. (A) G>A substitution on chr15:23931507 in NDN, representing imprinting: the variant nucleotide (A)
is in heterozygote state in the exomes and in homozygote in the transcriptomes. (B) C>T substitution on chrX:80373961in HMGN5, representing strong allelic
expression from the variant allele in both transcriptomes. (C) G>T onchr2:220431631 in OBSL1, representing LOH: the SNP is heterozygote in the normal exome
and transcriptome, and homozygote in the tumor exome and transcriptome. (D) C>T onchr1:9305335 in H6PD, representing tumor specific allelic expression:
the SNP is heterozygote in the exomes and normal transcriptome, and, homozygote in the tumor transcriptome. (E) C>T onchr17:7578203 in TP53 representing
somatic mutation, likely driving: the variant is not present in the normal exome and transcriptome, and transitions from hetero- to homozygote from the tumor
exome to tumor transcriptome. (F) A>G on chr1:160319987 in NCSTN representing RNA editing – the variant is not present in the exomes; it appears in the tumor
transcriptome only, suggesting potential tumor specific editing mechanism.

to tumor exome, respectively) in the immediate chromosomal
surroundings. Several strings of adjacently located SNPs were
observed in our dataset; an example is the gene string TNS1, PNKD,
ZNF142, and OBSL1, encompassing the region chr2:218682771 chr2:220431631 (rs1043537 is presented on Figure 2C). Of note,
somatic deletion of these genes was confirmed by the microarray
data available on the same sample through the integrative cBioPortal
for Cancer Genomics (http://www.cbioportal.-org/public-portal/).
This validation shows the capacity of the exome-to-transcriptome
alignment to independently indicate potential LOH, and, at the same
time, features one additional level of genomic data integration.
Another tumor related SNP preferential expression is defined by
variants providing growth advantage to the tumor cells. Such SNPs
could be distinguished through comparison between the normal
and the tumor transcriptome – while in the normal tissue they are
expected to retain their heterozygosity, accelerated growth of SNPexpressing tumor cells will acquire higher proportion of the variant
over the wild type alleles. In our dataset, 265 SNPs, six of which not
listed in the population databases, satisfied the criteria to be present
in heterozygote state in the exomes and the normal transcriptome,
vs homozygous expression in the tumor transcriptome. One
interesting example is the very rare silent substitution C>T at
chr1:9305335(rs138024142, Figure 2D) in the coding sequence of
the recently reported to be up-regulated in breast cancer glutamate
dehydrogenase H6PD [20]. The variant allele frequency is below
0.01% in general population; parallel in silico modeling of the local
genomic region with the wt and the variant nucleotide through the
modeling tool “RNAstructure” [21] showed reasonable probability
for alteration of the secondary RNA structure harboring the SNP.
J Metabol Sys Biol 1(1): 7 (2013)

Focused wet-lab studies are required to assess if rs138024144 variant
is implicated in expression regulation of H6PD, in normal or tumor
tissues.
Next, we sought to determine the efficiency of the integrative
analysis to outline somatic cancer changes. Compared to the
extensively performed searches for somatic mutations through
comparison of germ line and tumor DNA, RNA-sequencing called
SNPs allow estimation of allelic preferential expression, and, thus,
uncovering of potential driving (vs passenger) changes [22]. Similarly
to above described analyses, among the SNPs confidently called
in the tumor (but not in the normal) exome and transcriptome,
a particular subset of interest lies in the variants with higher var/
wt ratio in the transcriptome, due to the typically low var/wt ratio
in the encoding exome. A total of 6 SNPs, none of them present
in the population databases, satisfied our criteria for confident
somatic mutations. Of note, all of them presented with var/wt ratio
>2 in the tumor transcriptome. Of special interest is the missense
substitution V216M in the well-known breast cancer oncogene TP53
[23]; the IGV visualization is presented on Figure 2E. The mutation
affects the domain required for interaction with FBXO42 and is
predicted to be damaging; examination of the IGV files revealed
complete homozygous expression in the tumor exome, compared
to only several reads in the normal exome. While not present in
the population databases, V216M has been reported as a somatic
mutation in multiple tumor samples, including breast invasive
carcinoma, and is catalogued in the COSMIC database (http://www.
sanger.ac.uk/cosmic) [24]. Similarly, we were able to validate all the
rest of the somatic calls from our datasets in the COSMIC Database.
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RNA editing

Discussion

To highlight potential RNA editing events, we identified the
variants called in transcriptomes but in none of the exomes, with
a threshold of var/wt ratio>0.5 (See Figure 1). After removal of the
SNPs present in the Exome Variant Server (http://evs.gs.washington.
edu/EVS/) [25], 7427 such variants were shared between the tumor
and the normal transcriptomes, and additional 2384 were called in
the tumor transcriptome only. When we overlaid our results with
the known RNA editing events database DARNED [26], a total 1217
variants overlapped with our datasets. Two intriguing observations
attracted our attention in thus selected dataset. First, there was
apparent gene-centered clustering of RNA-exclusive events, and
second, high proportion of the putative RNA editing sites seemed to
be predominant, often to monozygotic level, of the variant (vs wt)
nucleotide harboring reads. To examine further these observations,
we blasted the surroundings of such SNPs against the entire human
genome. We found perfect match for the variant bearing allele, in
a different genomic locus. An example is the G>A substitution at
position chr13:25671320 residing in the coding sequence of PABPC3.
Blasting of the SNP calling reads revealed a match at a region of
chromosome 8 encoding the highly homologous gene from the same
family: PABPC1. Further investigation of more of these sequences
suggested that they likely originate from genomic regions highly
homologous to the expressed mRNA transcripts, thus representing
partial or entire pseudogene-like elements, or closely related
homologous genes from the same family/cluster. This explains why
these SNP-like calls often cluster in genes – reads derived from an
expressed pseudo-gene or homologous gene would generate similar
false-positive calls for every mismatch with the original transcript.

Despite the fact that the exome and transcriptome target largely
overlapping genomic regions, they contain genuinely distinct
information layers. While whole exome capture is designed based
on the knowledge on all coding genomic sequences, transcriptome
does not employ previous knowledge and captures the collection of
expressed genes in the studied sample at the moment of harvesting.
As such, any single transcriptome represents a snapshot of the
transient cell/tissue condition, and only roughly reflects the sample
representative genes’ and isoforms’ profile. In terms of number of
called variations, two major sources define the significant deviation
between the two datasets – the transcriptome will not cover variations
in genes that are not expressed, and the exome design does not
include most of the large untranslated (UTR), but expressed regions.
Additional factors contributing to the exome/transcriptome diversity
might be some randomly included non-targeted areas, differences in
the sequencing platform, variation call pipeline and filtering criteria.

To search for new high-confidence RNA editing events, we
focused on exonic variants, not listed in population or disease
datasets, and not present in DARNED. To remove potentially biased
calls, we visually examined the variation appearance through IGV,
and removed variants which did not satisfy the criteria for confident
RNA editing due to either presence in the exomes (false negative
call at the exome level), lack of sufficient exonic coverage, or, called
by parts of short read from the intronic 3’- or 5’-splice site. We also
blasted the SNP calling reads against the entire genome and retained
only SNPs called by uniquely mapped genes. Among the retained
high-confidence RNA editing SNPs, one interesting example is
the missense substitution S177G (1:160319987 A>G) in the gene
encoding nicastrin NCSTN. Of note, this change was called by very
few reads in the normal transcriptome, but over-dominated the
position in the tumor transcriptome (Figure 2F). Nicastrin cleaves
integral membrane proteins, including Notch receptors and betaamyloid precursor protein, and has been recently identified as a
cancer driver gene through genome-wide scan [27,28]. In addition,
a major recent study has shown that NSCTR regulates breast cancer
stem cell properties and tumor growth both in vivo and in vitro [29].
Thus, S177G in NCSTN is worthy focused investigation for cancer
driving potential. S177G has never been reported before, however,
another NCSTN variant – 1:160327023 A>G - has been reported in
DARNED as subject of RNA editing in cerebellum. Notably, both
variants represent the common A>I (functional A>G) change, known
as the most common RNA editing subject. Taking into account the
suggested NCSTN variants involvement in Alzheimer [30,31], there
is an apparent need of further investigation of disease implicated
NCSTN editing.
J Metabol Sys Biol 1(1): 7 (2013)

For the regions covered by the exome and transcriptome, the
observed deviations usually indicate important regulatory features.
In our set of normal/tumor/transcriptome/exome, cancer related
changes could be outlined through comparison between the normal
and tumor datasets, and expression-specific elements could be
found through exome-to-transcriptome comparison (Figure 3).
Transcriptome specific allelic expression is an important factor that
reflects advantage driven preferential dominance of certain alleles. At
nucleotide resolution, it involves one additional information layer
– the potential to highlight causative or contributing to the allelic
imbalance nucleotide changes. These changes should be carefully
distinguished from variants that randomly co-exist along with the
driving allele. While lab validation of such findings is definitely a
must, application of similar analyses on large-scale can tremendously
decrease the rate of random observations and select a finely narrowed
feature-set for further analyses.

Figure 3: Circos plots representing alignment of the number of variant
and wild type reads at each genomic position at which SNP is called. Wild
type read numbers are shown in blue for the exomes and in green for the
transcriptomes, and the variant reads are orange in the exomes and red in
the transcriptomes.
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Despite the array of integrative NGS analyses provided
advantages, on many occasions they need to be applied with caution.
Here, we highlight three important points worthy of consideration
when aligning NGS datasets. First, ample coverage for all compared
regions is necessary, to avoid methodological bias. While in many
cases low number of RNA-seq reads indicate low expression, it may
also reflect difficult to sequence transcripts. This consideration further
applies on preferentially expressed variants – either the nucleotide
change itself, or, coexisting allelic feature can provide sequencing
advantage or disadvantage compared to the wild type. In both cases,
alternative method and/or multi-samples comparisons are the first
step to confirm the authenticity of the observation.
Second, visual examination of the region of interest through IGV
or similar genome visualization tool is always helpful to determine
the confidence of the call (see Figure 2). Despite the growing number
of alignment, assembly and variant calling tools, filtering strategies
and confidence-boosting algorithms, false positive and false negative
variation calls are still a challenge for NGS.
Third, inherent feature of the short reads sequencing technologies
is the possibility for mis-alignment. In our analysis, this bias is
illustrated in the RNA-editing focused pipeline. When aligning
genomes to transcriptomes, it is essential to keep in mind that similar
expressed sequences usually derived from homologous or pseudogenes, can almost perfectly match to the transcript of interest,
mistaking for SNP a single mismatch between the transcript of
interest and the original site. This is even more emphasized for the
non-coding parts of the genome, which still lack sufficient population
data and the reference often contains rare variants disfavoring
the mapping of the reads to their original site. One approach that
definitely restricts such miscalls is local alignment using tools such as
BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat?hgsid=340320355&c
ommand=start) of the variant calling reads against the whole human
genome [32,33]. If a perfect match with another genomic location
is found, the SNP call should be treated with increased caution and
validated through alternative means.
The purpose of this report is to illustrate approaches that can
extract or validate important molecular features, such as expression
or growth advantage, imprinting, LOH, somatic changes, RNA
editing, through alignment of SNP calls in their allelic context at
exome and transcriptome level from the same individual (see Table
3). One additional advantage of the multi-NGS datasets format
from the same sample is that it provides means to validate rare or
unique findings in cases where no new sample collection is possible.
Further, each of the exemplified analytical pipelines can be separately
developed to rigorously define the corresponding type of changes in a
particular transcriptome dataset of interest. Moreover, the proposed
SNP-based pipelines can be integrated with expression information
derived from the transcriptome. Interlinking variation and expression
require multiple samples, and is outside of the scope of our singleindividual based analysis. In a multi-sample large scale analysis, it
holds tremendous potential to uncover regulatory networks through
analysis for co-existing and mutually exclusive features.
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